Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure

Efe Eworuke (), Emily C. Welch, Anne Tobenkin and Judith C. Maro
Additional contact information
Efe Eworuke: Center for Drug Evaluation and Research, Food and Drug Administration
Emily C. Welch: Harvard Pilgrim Health Care Institute
Anne Tobenkin: Center for Drug Evaluation and Research, Food and Drug Administration
Judith C. Maro: Harvard Pilgrim Health Care Institute

Drug Safety, 2019, vol. 42, issue 7, No 8, 897-906

Abstract: Abstract Introduction Neurological complications including seizures have been reported with ranolazine. We sought to quantify the risk of seizure-related hospitalizations or emergency department events following ranolazine exposure in the Sentinel System (2006–2015). Study Design and Setting Eligibility criteria were new use of ranolazine after 183 days washout period and absence of seizure diagnoses, anti-epileptic drugs, or seizure-related disorders during the baseline period. Results Among 52,155 ranolazine users, we identified 28 seizures in the 1–32 days after new ranolazine dispensing: 12 occurring in days 1–10 (high-risk window), 11 in days 11–20 (moderate-risk window) and 5 in the control window (days 21–32). Assuming an equal likelihood of seizure events across the 32-day observation window, we estimate an attributable risk of 0.9 excess cases per 10,000 exposed users. Using a self-controlled risk interval design with exact logistic regression, seizures were elevated in the high-risk window (relative risk [RR] 2.88 (95% confidence interval [CI] 1.01–8.33) compared with the control window. No significant increased risk was observed in the moderate window. Half of the seizure cases had a diagnosis of renal disease, although seizure risk was not significant (RR 3.20 [CI 0.82–14.01]). A majority of patients in both risk windows were 75 years or older. Conclusion Our study suggests risk among younger ranolazine patients is rare. Given the imprecision of the risk estimates, we interpret the elevated seizure risk following ranolazine exposure with caution. Further analysis in a larger elderly population is warranted.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00798-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:7:d:10.1007_s40264-019-00798-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00798-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().